Literature DB >> 19150954

The International Prognostic Index predicts outcome in aggressive adult T-cell leukemia/lymphoma: analysis of 126 patients from the International Peripheral T-Cell Lymphoma Project.

J Suzumiya1, K Ohshima, K Tamura, K Karube, N Uike, K Tobinai, R D Gascoyne, J M Vose, J O Armitage, D D Weisenburger.   

Abstract

BACKGROUND: The International Peripheral T-cell Lymphoma Project was organized to better understand the T-cell and natural killer (NK) cell lymphomas, and our task is to present the clinicopathologic correlations and therapeutic results for adult T-cell leukemia/lymphoma (ATL). PATIENTS AND METHODS: Among 1153 patients with T-cell or NK cell lymphomas, 126 patients (9.6%) with ATL were represented in this project. All were categorized as aggressive ATL, i.e. acute or lymphoma type, and 87% fell into the lymphoma type.
RESULTS: The median age was 62 years and the male to female ratio was 1.2 : 1. Significant prognostic factors for overall survival (OS) by univariate analysis were the presence of B symptoms (P = 0.018), platelet count <150 x 10(9)/l (P = 0.065), and the International Prognostic Index (IPI; P = 0.019). However, multivariate analysis indicated that only the IPI was an independent predictor of OS. Combination chemotherapy including anthracyclines was given as the initial therapy in 109 of the 116 patients (94%) who received treatment, and the overall and complete response rates were 70% and 34%, respectively. However, there was no survival benefit for those receiving an anthracycline-containing regimen.
CONCLUSION: Patients with aggressive ATL have a poor clinical outcome and the IPI is a useful model for predicting outcome in ATL of the lymphoma type.

Entities:  

Mesh:

Year:  2009        PMID: 19150954     DOI: 10.1093/annonc/mdn696

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  15 in total

1.  Long-term survival in patients with peripheral T-cell non-Hodgkin lymphomas after allogeneic hematopoietic stem cell transplant.

Authors:  Esperanza B Papadopoulos; Miguel-Angel Perales; Jenna D Goldberg; Joanne F Chou; Steven Horwitz; Julie Teruya-Feldstein; Juliet N Barker; Farid Boulad; Hugo Castro-Malaspina; Sergio Giralt; Ann A Jakubowski; Guenther Koehne; Marcel R M van den Brink; James W Young; Zhigang Zhang
Journal:  Leuk Lymphoma       Date:  2012-01-31

Review 2.  New targets of therapy in T-cell lymphomas.

Authors:  Jack Erter; Lapo Alinari; Kamruz Darabi; Metin Gurcan; Ramiro Garzon; Guido Marcucci; Mark A Bechtel; Henry Wong; Pierluigi Porcu
Journal:  Curr Drug Targets       Date:  2010-04       Impact factor: 3.465

3.  Evolving Therapy of Peripheral T-cell Lymphoma: 2010 and beyond.

Authors:  Francine Foss
Journal:  Ther Adv Hematol       Date:  2011-06

Review 4.  The Value and Relevance of the T Cell Lymphoma Registries and International Collaborations: the Case of COMPLETE and the T-Cell Project.

Authors:  Monica Bellei; Chadi Nabhan; Emanuela Anna Pesce; Luana Conte; Julie M Vose; Francine Foss; Massimo Federico
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

5.  HTLV-1-Associated Lymphoma Presented as Massive Lymphadenopathy.

Authors:  Pei Ting Chen; David Onukogu; Gregory Gotlieb; Rashid Chaudhry; Vijay Jaswani; Karan Josan; Cheema Akhtar; Jen Chin Wang
Journal:  J Investig Med High Impact Case Rep       Date:  2021 Jan-Dec

6.  Rapid Remission in Peripheral T-Cell Lymphoma of the Nasal Type by the Bortezomib plus CHOP Therapy.

Authors:  Li-Jun Xue; Xiao-Bei Mao; Xiao-Bei Liu; Quan-Sheng Su; Hong-Ju Yu; Ji-Hong Yang
Journal:  Case Rep Med       Date:  2010-12-26

Review 7.  Prognostic markers in peripheral T-cell lymphoma.

Authors:  Pier Paolo Piccaluga; Claudio Agostinelli; Anna Gazzola; Claudia Mannu; Francesco Bacci; Elena Sabattini; Stefano A Pileri
Journal:  Curr Hematol Malig Rep       Date:  2010-10       Impact factor: 3.952

8.  Elevated LDH and paranasal sinus involvement are risk factors for central nervous system involvement in patients with peripheral T-cell lymphoma.

Authors:  J H Yi; J H Kim; K K Baek; T Lim; D J Lee; Y C Ahn; K Kim; S J Kim; Y H Ko; W S Kim
Journal:  Ann Oncol       Date:  2011-01-10       Impact factor: 32.976

9.  Variation in dicer gene is associated with increased survival in T-cell lymphoma.

Authors:  Xi Li; Xiaobo Tian; Bo Zhang; Yanqi Zhang; Jieping Chen
Journal:  PLoS One       Date:  2012-12-10       Impact factor: 3.240

10.  Identification of multiple subclones in peripheral T-cell lymphoma, not otherwise specified with genomic aberrations.

Authors:  Noriaki Yoshida; Akira Umino; Fang Liu; Kotaro Arita; Kennosuke Karube; Shinobu Tsuzuki; Koichi Ohshima; Masao Seto
Journal:  Cancer Med       Date:  2012-09-26       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.